BRVO - BRANCH RETINAL VEIN OCCLUSION
Clinical trials for BRVO - BRANCH RETINAL VEIN OCCLUSION explained in plain language.
Never miss a new study
Get alerted when new BRVO - BRANCH RETINAL VEIN OCCLUSION trials appear
Sign up with your email to follow new studies for BRVO - BRANCH RETINAL VEIN OCCLUSION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New eye drug EYE201 aims to tackle blinding swelling
Disease control OngoingThis early-stage study tests a new drug called EYE201, given as three eye injections over 12 weeks, for people with vision loss due to swelling in the back of the eye. The study includes patients with three different eye conditions: branch retinal vein occlusion, diabetic macular…
Matched conditions: BRVO - BRANCH RETINAL VEIN OCCLUSION
Phase: PHASE1, PHASE2 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New syringe vs vial: which is safer for eye injections?
Symptom relief OngoingThis study tests whether giving ONS-5010 (a bevacizumab eye injection) from a pre-filled syringe is as safe as using a standard vial. About 120 people with wet age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion will take part. The main goal…
Matched conditions: BRVO - BRANCH RETINAL VEIN OCCLUSION
Phase: PHASE3 • Sponsor: Outlook Therapeutics, Inc. • Aim: Symptom relief
Last updated May 20, 2026 11:54 UTC